<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864901</url>
  </required_header>
  <id_info>
    <org_study_id>S-16-10</org_study_id>
    <nct_id>NCT02864901</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo Controlled, Clinical Trial of an Antiplaque Chewing Gum (30 mg) - Phase 2 Proof of Concept in a Generally Healthy Patient Population</brief_title>
  <acronym>APCG</acronym>
  <official_title>A Double-Blind, Randomized, Placebo Controlled, Clinical Trial of an Antiplaque Chewing Gum (30 mg) - Phase 2 Proof of Concept in a Generally Healthy Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2 two-armed placebo-controlled, double-blind, randomized (1:1),
      multiple dose, single center study to evaluate the safety and proof of concept in a chewing
      gum formulation 3 times per day over 4 treatment days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>21 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in plaque regrowth from baseline in the Quigley Hein-Turesky Plaque Index (QHT)</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>change in plaque regrowth based on sub-scores from specific regions of the upper jaw, lower jaw, buccal and lingual surface based on the QHT</measure>
    <time_frame>21 Days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Plaque Regrowth</condition>
  <arm_group>
    <arm_group_label>KSL-W 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 times per day over 4 treatment days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chewing Gum Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 times per day over 4 treatment days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSL-W</intervention_name>
    <description>Plaque reducing gum</description>
    <arm_group_label>KSL-W 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chewing Gum Placebo</intervention_name>
    <arm_group_label>Chewing Gum Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A negative urine pregnancy test (females of childbearing potential only)

          -  A negative urine drug test

          -  On a reliable form of birth control for at least 30 days prior to the start of the
             study and willing to use a reliable form of contraception for the duration of the
             study (Females of childbearing potential only), with reliable contraception defined
             as:

          -  Abstinence which has been the customary lifestyle of choice

          -  Oral contraceptive, either estrogen progesterone combined, or progesterone alone

          -  Injectable progesterone

          -  Implants of levonorgestrel

          -  Estrogenic vaginal ring

          -  Percutaneous contraceptive patches

          -  Intrauterine device or intrauterine system

          -  Double barrier method [condom or occlusive cap (diaphragm or cervical vault caps) plus
             spermicidal agent (foam, gel, film, cream, suppository)]

          -  Male partner sterilization at least 6 months prior to the female subject's entry into
             the study, and this male is the sole partner for that subject

          -  Post-menopausal for at least two years

          -  Good health, as determined by pertinent medical history, physical examination, and
             vital signs

          -  A minimum of 20 natural teeth with 6 scorable surfaces per tooth

          -  Sufficient number of opposing posterior teeth to chew on both sides of the mouth as
             determined by the examining dentist

          -  Teeth that have gross caries, full crowns or extensive restorations on facial and/or
             lingual surfaces, orthodontic bands, and third molars are not included in the tooth
             count

          -  Subject must have refrained from all oral hygiene procedures 12 to 16 hours prior to
             screening visit

          -  Plaque Index of 1.95 or greater (Turesky et al-1970)

          -  Willing to forgo any optional dental procedures during the study period, such as
             dental prophylaxis or teeth whitening

          -  Ability to comprehend and a willingness to sign an informed consent, which includes
             the Authorization for the Release of Health Information document

          -  Ability to access the internet to complete the drug compliance information

          -  Willingness to comply with all study procedures

        Exclusion Criteria:

        E01 Phenylketonuria E02 Acute or chronic medical conditions, organ system disease, or
        medications that, in the principal investigator's opinion, would impair the subject's
        ability to participate E03 TMD E04 Self-reported allergy to sucralose or mint flavors E05
        Self-reported use of tobacco products including e-cigarettes E06 Use of any type of
        anticoagulant medications (eg clopidogrel) E07 Routine use of proton pump inhibitors E08
        Allergic to any component of the study drug E09 Gross oral pathology, including widespread
        caries or chronic neglect, extensive restoration, pre-existing gross plaque or calculus, or
        soft or hard tissue tumor of the oral cavity E010Orthodontic appliances or removable
        partial dentures that will compromise the ability of the potential subject to participate
        in the study E011Periodontitis as indicated by periodontal pockets greater than 4
        millimeters on more than one site E012 Receipt of any investigational drug/test product
        within 30 days prior to study entry with study entry defined as Day 0, or currently
        participating in either the active or follow-up phase of any other investigational study or
        planning to participate in any other investigational study during participation in this
        trial E013 Participation in the Phase 1/2a antiplaque study E014 Receipt of antibiotics
        within 30 days prior to study entry E015 Need for antibiotic prophylaxis prior to invasive
        dental procedures E016 Receipt of prescription antibacterial oral products (eg products
        containing chlorhexidine) within 30 days prior to study entry E017 Pregnant or
        breast-feeding female E018 An employee of the study site directly involved with the study
        E019 Inability to comply with assigned treatment regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery L Milleman, DDS, MPA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salus Research</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

